REVEAL GENOMICS® HER2DX® Genomic Test to be validated in Pivotal ECOG-ACRIN COMPASSHER2 pCR TRIAL in HER2+ breast cancer

• ‍The CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX^® genomic test as a key secondary endpoint.
• HER2DX^® pCR-score and HER2DX^® risk-score will be analyzed in baseline pre-treatment samples from trial participants, linking these scores directly to patient outcome.
• The inclusion of HER2DX^® in the CompassHER2 pCR Trial seeks to corroborate initial findings to provide Level 1 evidence in supporting the selection of an optimized therapy regimen.
• The CompassHER2 pCR Trial places the ECOG-ACRIN Cancer Research Group at the forefront of assessing an optimized therapy regimen with reduced chemotherapy across nearly 2200 patients with HER2-positive breast cancer.

Barcelona, Spain. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX^® within the framework of the ongoing CompassHER2 pCR Trial. This study is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer, comprising nearly 1400 member institutions in the United States and around the world.

The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer. Now in follow-up, this trial seeks to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with a pathologic complete response (pCR) after 3 months of pre-operative treatment with standard THP (single-agent taxane chemotherapy plus trastuzumab and pertuzumab [HP], both targeted drugs). If testing shows pCR at the time of surgery, patients will then complete a year of HP plus hormonal therapy and radiation, if indicated.

If the study's results validate this approach, it would allow patients to have fewer side effects and better quality of life. The neoadjuvant setting offers the opportunity to use pCR as a functional biomarker to identify patients with excellent outcomes and refine treatment to maximize benefit and minimize toxicity. The primary objective of the trial is 3-year recurrence-free survival, and pCR is a secondary endpoint.

In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX^®genomic test as a key secondary correlative endpoint. HER2DX^® pCR-score and HER2DX^® risk-score will be analyzed in baseline pre-treatment samples from most trial participants, linking these scores directly to patient outcomes.

The principal investigator of the CompassHER2 pCR Trial, Dr. Nadine M. Tung, commented, "Integrating HER2DX^®'s predictive capabilities into our trial represents a significant opportunity in our quest to tailor treatments to the individual, not just the cancer type. If proven and validated, this assay could fundamentally change our approach to treating HER2-positive breast cancer."

Previous retrospective validation involving 765 patients with early-stage HER2+ breast cancer who received neoadjuvant therapy highlighted the HER2DX® pCR-score's ability to distinguish patients with a high pCR rate of 80-90% after treatment with single taxane, trastuzumab, and pertuzumab.

REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX^® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment. By providing a more nuanced understanding of HER2-positive cancers, HER2DX^® will play a crucial role in shaping the future of personalized therapy and improving patient outcomes."

HER2DX^® in the CompassHER2 pCR Trial: Guiding the way to personalized medicine

The inclusion of HER2DX^® in the CompassHER2 pCR Trial seeks to corroborate these initial findings, providing Level 1 evidence to support the selection of an optimized therapy regimen. Specifically, it seeks to validate the use of a single taxane-based regimen over traditional multi-agent chemotherapy, potentially revolutionizing the treatment approach for HER2-positive breast cancer by enabling more personalized, less intensive treatment strategies.

This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.

‍